Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer

With approximately 240,890 new cases expected in 2011, prostate cancer remains the leading cause of non-melanoma cancer deaths in men. Immunotherapies using viral vector-based delivery systems targeting tumor-specific antigens are being studied. Viral vector-based delivery systems present tumor-targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Amato, Robert J., Stepankiw, Mika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256982/
https://www.ncbi.nlm.nih.gov/pubmed/22253556
http://dx.doi.org/10.4137/CMO.S7654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256982/
https://www.ncbi.nlm.nih.gov/pubmed/22253556
http://dx.doi.org/10.4137/CMO.S7654

Ejemplares similares